Carregant...

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia

Chronic myelogenous leukemia (CML) requires the BCR/ABL tyrosine kinase for disease onset and maintenance. As a result, CML can be successfully treated with tyrosine kinase inhibitors (TKIs) such as imatinib. Most patients are maintained in a disease-suppressed state on daily TKI therapy for several...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cell Oncol
Autors principals: Ross, Theodora S, Mgbemena, Victoria E
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4904890/
https://ncbi.nlm.nih.gov/pubmed/27308345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/23723548.2014.963450
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!